On the stock market since 2014, it operates in the world of health and science. It has 19 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 197% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 197% a year on average.
Sales run at $19.6M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 23 buys and 19 sells. Management buying with its own money is usually read as a good sign.
A loss of $14.5M against $19.6M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 34% above the average analyst price target.
On our five-subject report card, AGRX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AGRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.